Cytokines: from Basic Mechanisms of Control to New Therapeutics

This is a free sample of content from Cytokines: From Basic Mechanisms of Control to New Therapeutics. Click here for more information on how to buy the book.

Index

A Cryopyrin-associated periodic syndromes (CAPS), AKT 262–263 g chain family cytokine signaling, 9 CTCL. See Cutaneous T-cell lymphoma T-cell development role, 279 Cutaneous T-cell lymphoma (CTCL), interleukin-15 role, AMPs. See Antimicrobial peptides 448 Antimicrobial peptides (AMPs), 456 Cytokine release syndrome (CRS), interleukin-6 therapeutic Arid5a, 94 targeting, 93, 94 Atopic dermatitis Cytokine studies interleukin-17 studies, 130 agonist development, 458–459 interleukin-22 therapeutic targeting, 169 alarmins, 456–457 antagonist development, 459–460 assay development, 457 B definition, 455–456 B cell historical perspective, 456 g chain family cytokine function, 16–18 mimics, 457 interferon-g in activation, 226–227 mutation studies, 458 tumor necrosis factor in development and function, 105 signaling studies, 457–458 BCL11B, 280–281 b Common family cytokines. See also specific cytokines cancer studies, 46 D functions, 43–44 Daclizumab, 21 nervous system function, 46–47 DC. See Dendritic cell overview, 40–43 Dendritic cell (DC) receptors classical dendritic cells activation, 48–49, 51 cDC1 development and function, 397–398 assembly, 48 cDC2 development and function, 398–399 assembly, 48–51 GM-DCs, 403–404 interactions with other receptors, 47–48 human cell features, 401–402 proximal activation of signaling, 52–53 identification sepsis and inflammation studies, 44–45 mouse bone marrow, 396–397 therapy, 41–42, 53–56 surface markers for in vivo identification, 403 BLIMP1, 15 maturation, 404–406 Briakinumab, 151 Mo-DCs, 403 g chain family cytokine function, 19 C interferon-g in activation, 226 Candida albicans, interleukin-17 studies, 129 long noncoding RNA regulation of differentiation, CAPS. See Cryopyrin-associated periodic syndromes 297–298 Castleman disease, toclizumab therapy, 89 plasmacytoid dendritic cells CD. See Crohn’s disease development and function, 399–400 Ciliary neurotrophic factor (CNTF) human cell features, 402 overview, 72–73 subsets, 395 mutations and disease, 76 Diabetes type 1, g chain family cytokine studies, 20–21 trans-signaling, 75 Diabetic foot ulcer (DFU), interleukin-20 family member CISH, 317–318 therapy, 174–175 CNTF. See Ciliary neurotrophic factor Crohn’s disease (CD) g chain family cytokine studies, 20 E interleukin-10 studies, 159, 161–162 Ectodysplasin, 104 interleukin-22 therapy, 170–172 EPO. See Erythropoietin CRS. See Cytokine release syndrome Erythropoietin (EPO), receptor, 47–48

463

© 2018 by Cold Spring Harbor Laboratory Press. All rights reserved. This is a free sample of content from Cytokines: From Basic Mechanisms of Control to New Therapeutics. Click here for more information on how to buy the book. Index

F IFN-a. See Interferon-a Familial Mediterranean fever (FMF), 263–264 IFN-g. See Interferon-g FGK 4.5, 444 IL-1. See Interleukin-1 FMF. See Familial Mediterranean fever IL-2. See Interleukin-2 Follicular lymphoma, interferon-a therapy, 437 IL-3. See Interleukin-3 FOXP3, 11, 332 IL-4. See Interleukin-4 IL-5. See Interleukin-5 G IL-6. See Interleukin-6 g Chain family cytokines. See also specific cytokines IL-7. See Interleukin-7 autoimmune disease role, 19–22 IL-9. See Interleukin-9 B-cell function, 16–18 IL-10. See Interleukin-10 gene expression mediation, 9–10 IL-11. See Interleukin-11 natural killer cell function, 18–19 IL-12. See Interleukin-12 overview, 1–5 IL-13. See Interleukin-13 receptors, 5–7 IL-15. See Interleukin-15 signaling, 7–9 IL-17. See Interleukin-17 structure, 2 IL-19. See Interleukin-19 T-cell function IL-20. See Interleukin-20 CD8þ T-cell development and differentiation, 16 IL-21. See Interleukin-21 development, 10–11 IL-22. See Interleukin-22 helper T-cell differentiation, 12–16 IL-23. See Interleukin-23 Tregs, 11–12 IL-24. See Interleukin-24 therapy, 22–25 IL-26. See Interleukin-26 GATA3 IL-28. See Interleukin-28 helper T cells IL-29. See Interleukin-29 differentiation role, 330–332 IL-33. See Interleukin-33 expression by noncanonical Th cell subtypes, IL-37. See Interleukin-37 332–333 ILC. See Innate lymphoid cell T-cell development role, 273–274, 277–280 Inflammation GCA. See Giant cell arteritis autoinflammatory disease. See Interleukin-1 Giant cell arteritis (GCA), toclizumab therapy, 92 b common family cytokine studies, 44–45 GM-CSF. See Granulocyte macrophage colony-stimulating granulocyte macrophage colony-stimulating factor factor role, 45 Graft-versus-host disease (GVHD), interleukin-22 interleukin-17 studies protective effects, 173–174 IL-17B, 131 Granulocyte macrophage colony-stimulating factor IL-17C, 131–132 (GM-CSF) IL-17D, 132 cancer immunotherapy, 439–440 IL-17E, 132 cancer studies, 46 tumor microenvironment, 414 functional overview, 43–44 tumor necrosis factor role, 103 nervous system function, 46–47 Innate lymphoid cell (ILC) receptor, 48–53 cytokine regulation sepsis and inflammation role, 45 group 1 cells, 382–383 therapeutic targeting, 53–55 group 2 cells, 383–385 GVHD. See Graft-versus-host disease group 3 cells, 385–387 interferon, 382–383 H interleukin-1, 387 HEB, T-cell development role, 280–281 interleukin-2, 381–382, 386 Hepatitis interleukin-4, 384–385 interferon-g therapy, 176 interleukin-5, 384, 389 interleukin-22 protective effects, 173 interleukin-7, 381–382, 386 HHV8. See Human herpes virus 8 interleukin-9, 384–385 Human herpes virus 8 (HHV8), interleukin-6, 73 interleukin-12, 388 interleukin-13, 384 interleukin-15, 381–382 I interleukin-17, 386–387 ID2, 400 interleukin-22, 386–387 IFN. See Interferon overview, 380–382

464

plasticity modulation, 387–388 interleukin-1 receptor antagonist deficiency, 265 tumor immunity, 388–389 intrinsic inflammasomopathies, 261–265 functional overview, 379–380 Majeed syndrome, 265 subsets, 380 mevalonate kinase deficiency, 266 Th cell relationship, 335–336 NLRC4-associated autoinflammatory Innate repair receptor (IRR), 47–48 diseases, 264 Interferon (IFN) NLRP12-associated autoinflammatory cancer studies, 197 disorder, 265 classes, 203–204, 206 overview, 261 classification, 436 pyogenic arthritis, pyoderma gangrenosum and innate lymphoid cell regulation, 382–383 acne syndrome, 265–266 long noncoding RNA regulation, 302–303 tumor necrosis factor receptor-associated periodic signaling, 196–197, 205 syndrome, 267 Interferon-a (IFN-a), cancer immunotherapy cellular sources, 240–241 follicular lymphoma, 437 expression regulation, 246 Kaposi sarcoma, 437 family members, 239, 255–256 melanoma, 437–438 immune regulation, 245–246 toxicity, 438 immune stimulation by inflammasome-dependent Interferon-g (IFN-g) cytokines, 260 antibodies, 457 inflammasome-dependent processing, 256–260 cancer immunoediting role innate lymphoid cell regulation, 387 elimination phase, 229–231 nuclear function, 248 equilibrium, 231–232 overview, 239–240 escape, 232–233 signaling regulation, 247–248 overview, 227–229 Interleukin-2 (IL-2) cancer studies, 176–177 autoimmune disease studies, 19–22 cellular sources, 220–221 cancer immunotherapy gene, 219 low-dose trials, 435–436 immune cell activation melanoma, 434–435 B cell, 226–227 overview, 433–434 dendritic cell, 226 renal cell carcinoma, 434–435 macrophage, 225–226 CD8þ T cell T cells function, 16 CD8þ T cells, 227 response to virus infection, 362–365, 370, 372 helper T cells, 227 functional overview, 2–3 Tregs, 227 helper T cell interferon regulatory factor regulation, 211–212 differentiation role, 12–13, 15–16 posttranslational modification, 220 fate determination, 329 receptor history of study, 1–2 activation, 224 innate lymphoid cell regulation, 381–382, 386 signaling pathway, 223, 225 natural killer cell function, 18 structure and function, 221–223 receptors, 1–2, 5–6 types, 175 regulatory T-cell regulation, 346–350 virus infection treatment, 175–176 therapy, 22–25 Interferon regulatory factor (IRF) Treg function, 11–12, 14–15 interferon-g regulation, 211–212 Interleukin-3 (IL-3) structure, 206 cancer studies, 46 type I interferon regulation functional overview, 44 cytosolic DNA recognition, 210–211 nervous system function, 46–47 cytosolic RNA recognition, 208–210 receptor, 48–53 Toll-like receptor signaling, 206–208 sepsis and inflammation role, 45 type III interferon regulation, 212 therapeutic targeting, 55 types, 206 Interleukin-4 (IL-4) Interleukin-1 (IL-1) B-cell function, 16–18 autoinflammatory disease studies functional overview, 3–4 cryopyrin-associated periodic syndromes, 262–263 innate lymphoid cell regulation, 384–385 extrinsic inflammasomopathies, 265–267 macrophage function, 19 familial Mediterranean fever, 263–264 natural killer cell function, 18–19

465

Interleukin-4 (IL-4) (Continued) cellular sources, 160 receptors, 6 family members, 157–159 T helper cell differentiation role, 12–14, 329 receptors, 158–159 therapy, 25 structure, 158 Interleukin-5 (IL-5) systemic lupus erythematosus therapeutic targeting, 163 functional overview, 44 therapy innate lymphoid cell regulation, 384, 389 Crohn’s disease, 159, 161–162 nervous system function, 46–47 mechanism of action in autoimmune disease, 159 receptor, 48–53 rheumatoid arthritis, 162–163 therapeutic targeting, 55–56 strategies Interleukin-6 (IL-6) antibody-conjugated IL-10, 164–165 antibodies, 457 bacteria expression for intestinal delivery, cloning of complex components, 66–67 163–164 expression regulation, 86–87 ulcerative colitis, 159, 161 family of cytokines. See also speciﬁc cytokines Interleukin-11 (IL-11) mutations and disease, 75–76 mutations and disease, 75–76 overview, 72 trans-signaling, 75 plasticity, 72–73 Interleukin-12 (IL-12) human herpes virus 8, 73 cancer immunotherapy, 438–439 overview, 64–66, 83–85 cancer studies receptor complex antitumor immunity, 141 gp130 subunit, 69 cross-regulation with interleukin-23, 148–150 signaling, 68–69, 85–86 receptor expression, 144–145 soluble receptor, 73–74 therapeutic targeting, 150 structure, 68 family members, 139 trans-signaling, 69–71, 74–75 innate lymphoid cell regulation, 388 therapeutic targeting overview, 139–140 cytokine release syndrome, 93, 94 Interleukin-13 (IL-13), innate lymphoid cell regulation, 384 rationale, 88–89 Interleukin-15 (IL-15) sepsis, 93–94 cancer immunotherapy toclizumab therapy clinical trials, 442–443 Castleman disease, 89 combination therapy, 443–444 giant cell arteritis, 92 immune response, 441–442 juvenile idiopathic arthritis, 90 optimization, 443 myocardial infarction, 94 overview, 440–441 neuromyelitis optica, 92 preclinical studies, 441 polymyalgia rheumatica, 92–93 toxicity, 441 rheumatoid arthritis, 89–90 CD8þ T cell systemic sclerosis, 90–91 function, 16 Interleukin-7 (IL-7) response to virus infection, 368–370, 372–373 B-cell function, 16–18 cutaneous T-cell lymphoma role, 448 functional overview, 4 dendritic cell function, 19 innate lymphoid cell regulation, 381–382, 386 functional overview, 4–5 receptor, 6, 458 innate lymphoid cell regulation, 381–382 T-cell function receptors, 6 þ CD8 T-cell function, 16, 365–368, 372–373 regulatory T-cell regulation, 353–354 development role, 279–280 Interleukin-17 (IL-17) overview, 10–11 cellular sources regulatory T-cell regulation, 351–353 IL-17A, 122–123 Interleukin-9 (IL-9) IL-17B, 124 functional overview, 4 IL-17C, 124 innate lymphoid cell regulation, 384–385 IL-17D, 124 receptors, 6 IL-17E, 123–124 T helper cell differentiation role, 12–14 IL-17F, 122 Interleukin-10 (IL-10) infection studies cancer IL-17A, 129 role, 165–166 IL-17E, 132 therapeutic targeting, 166 IL-17F, 128–129

466

inﬂammation studies Interleukin-28 (IL-28), cellular sources, 160 IL-17B, 131 Interleukin-29 (IL-29), cellular sources, 160 IL-17C, 131–132 Interleukin-33 (IL-33) IL-17D, 132 cancer studies, 245 IL-17E, 132 cellular sources, 240–241 innate lymphoid cell regulation, 386–387 expression regulation, 246 overview of family, 121–122 nuclear function, 248 signaling overview, 239–240 IL-17A, 124–125 regulatory T-cell regulation, 354–355 IL-17B, 126 signaling regulation, 247–248 IL-17C, 126 T helper cell responses IL-17D, 126 Th1, 242–243 IL-17E, 125–126 Th2, 241–242 IL-17F, 124–125 visceral adipose tissue homeostasis role, 243–244, 355 overview, 124 wound healing role, 244–245 regulation, 127–128 Interleukin-37 (IL-37) skin disease studies, 129–131 cellular sources, 240 Interleukin-19 (IL-19), cellular sources, 160 nuclear function, 248 Interleukin-20 (IL-20) IPEX syndrome, 332 cellular sources, 160 IRF. See Interferon regulatory factor diabetic foot ulcer management, 174–175 IRR. See Innate repair receptor psoriasis role and therapeutic targeting, 168–169 rheumatoid arthritis role and therapeutic targeting, J 169–170 JAK Interleukin-21 (IL-21) b common family cytokine signaling, 51–52 autoimmune disease studies, 19–22 g chain family cytokine signaling, 7, 9 B-cell function, 16–18 overview of JAK-STAT pathway, 187–189, 314–315 cancer immunotherapy, 439 therapeutic targeting, 25 CD8þ T-cell function, 16 therapeutic targeting in cancer, 444–447 dendritic cell function, 19 JIA. See Juvenile idiopathic arthritis functional overview, 5 Juvenile idiopathic arthritis (JIA), toclizumab therapy, 90 natural killer cell function, 18–19 receptors, 7 T helper cell differentiation role, 15–16 K Interleukin-22 (IL-22) Kaposi sarcoma, interferon-a therapy, 437 atopic dermatitis therapeutic targeting, 169 KIT, T-cell development role, 277, 279, 282–284 cellular sources, 160 inﬂammatory bowel disease therapy, 170–172 innate lymphoid cell regulation, 386–387 L protective effects lncRNA. See Long noncoding RNA graft-versus-host disease, 173–174 Long noncoding RNA (lncRNA) hepatitis, 173 cell differentiation role with cytokines pancreatitis, 173 dendritic cell, 297–298 psoriasis role and therapeutic targeting, 168–169 erythrocytes, 296 Interleukin-23 (IL-23) hematopoiesis, 295–296 cancer studies macrophage, 297 cellular sources, 142, 144 short-lived myeloid cells, 296–297 clinical relevance of expression, 142–143 T cells cross-regulation with interleukin-12, 148–150 CD8þ T cell, 298 receptor expression, 144–147 NeST, 298, 301 therapeutic targeting, 150 Th1, 298, 301 tumor promotion, 141–142, 145, 147–148 Th2, 301 tumor suppression, 142 Th17, 301 overview, 139–140 Treg, 302 Interleukin-24 (IL-24) cytokine production regulation by lncRNAs antitumor activity, 166–168 AS-IL-1a, 305 cellular sources, 160 IL-1b-RBT46, 305 Interleukin-26 (IL-26), cellular sources, 160 lnc-IL-7R, 305

467

Long noncoding RNA (lncRNA) (Continued) PSTPIP1, 266 lncRNA-Cox2, 304 PTEN, 346 lncRNA-EPS, 306 Pyogenic arthritis, pyoderma gangrenosum and acne NEAT1, 305 (PAPA) syndrome, 265–266 NKILA, 305 PACER, 304–305 THRIL, 304 R cytokine regulation of RNAs RA. See Rheumatoid arthritis interferon, 302–303 Regulatory T cell. See T cell tumor necrosis factor a, 302 Renal cell carcinoma, interleukin-2 therapy, 434–435 diseases, 306–307 Rheumatoid arthritis (RA) overview, 293–295 g chain family cytokine studies, 20–21 prospects for study, 307–308 interleukin-10 studies, 162–163 therapeutic targeting, 307 interleukin-17 studies, 131 interleukin-20 role and therapeutic targeting, 169–170 toclizumab therapy, 89–90 M RNA. See Long noncoding RNA Macrophage. See also Tumor-associated macrophage RORgt, Th cell studies interferon-g in activation, 225–226 differentiation role, 331–332 long noncoding RNA regulation of differentiation, 297 expression by noncanonical Th cell subtypes, 332–333 Majeed syndrome, 265 Melanoma S interferon-a therapy, 437–438 interleukin-2 therapy, 434–435 Sepsis Morrbid, 296 b common family cytokine studies, 44–45 MS. See Multiple sclerosis interleukin-6 therapeutic targeting, 93–94 Multiple sclerosis (MS) SLE. See Systemic lupus erythematosus b common family cytokines studies, 45 SOCS g chain family cytokine studies, 21 SOCS1 MYB, T-cell development role, 282 functional overview, 316 Myocardial infarction, toclizumab therapy, 94 genome-wide association studies, 320 promoter hypermethylation and tumorigenesis, 320 T-cell regulation N antitumor immunity, 319–320 Natural killer cell, b chain family cytokine function, 18–19 differentiation, 314 NEAT1, 305 Tregs, 315 NeST, 298, 301, 303 SOCS3 Neuromyelitis optica (NMO), toclizumab therapy, 92 cancer studies, 321 Neutrophil. See Tumor-associated neutrophil functional overview, 192, 316, 320–321 NLRC4, 259–261, 264 genome-wide association studies, 321 NLRP3, 258–263 helper T-cell regulation, 321 NLRP12-associated autoinﬂammatory disorder, 265 types, 315–316 NMO. See Neuromyelitis optica SSc. See Systemic sclerosis Notch, T-cell development role, 274, 276, 282 STAT NRAV, 303 chromatin remodeling, 194–195 NRON, 303 g chain family cytokine signaling, 7–9 NRP1, 386 gene expression mediated, 9–10 interferon signaling, 196–197 intracellular localization, 194 P mutations PACER, 304–305 gain-of-function mutations Pancreatitis, interleukin-22 protective effects, 173 cancer, 195 PMR. See Polymyalgia rheumatica infectious disease, 195–196 Polymyalgia rheumatica (PMR), toclizumab therapy, 92–93 types, 195 PRC2, 294 negative regulation, 192 Psoriasis overview, 187–189 interleukin-17 studies, 129–130, 132 overview of JAK-STAT pathway, 314–315 interleukin-20 role and therapeutic targeting, 168–169 posttranslational modiﬁcations interleukin-23 therapeutic targeting, 151 glycosylation, 192

468

lysine and arginine, 191–192 helper T cell phosphorylation differentiation serine, 189 cross-regulation, 332 STAT1, 190 cytokine-mediated positive feedback, 330 STAT2, 190 STATs in fate determination, 328–330 STAT3, 190 transcription factors, 330–332 STAT5A, 190 effector T-cell relationship with Tfh cells, 334–335 STAT5B, 190 epigenetics and cell plasticity, 333–334 STAT6, 190–191 functions by type, 328 tyrosine, 192 innate lymphoid cell relationship, 335–336 SUMOylation, 192 types and cytokine production, 327–328 Th cell fate determination, 328–330 interferon-g in activation therapeutic targeting in cancer, 444–447 CD8þ T cells, 227 unphosphorylated STATs helper T cells, 227 gene expression regulation Tregs, 227 negative, 193–194 interleukin-33 and T helper cell responses positive, 192–193 Th1, 242–243 overview, 192 Th2, 241–242 U-STAT3 in mitochondria, 194 long noncoding RNA regulation of differentiation Systemic lupus erythematosus (SLE) CD8þ T cell, 298 g chain family cytokine studies, 20 NeST, 298, 301 interleukin-10 therapeutic targeting, 163 Th1, 298, 301 Systemic sclerosis (SSc), toclizumab therapy, 90–91 Th2, 301 Th17, 301 Treg, 302 T regulatory T-cell differentiation and homeostasis TACI, 109 control by cytokines TAM. See Tumor-associated macrophage interleukin-2, 346–350 TAN. See Tumor-associated neutrophil interleukin-7, 351–353 T cell interleukin-15, 353–354 interleukin-33, 354–355 CD8þ T-cell response to virus infection overview, 345–346 acute infection, 361–362 therapeutic targeting, 355–356 chronic infection, 370–372 transforming growth factor b, 350–351 interleukin-2, 362–365, 370, 372 SOCS regulation interleukin-7, 365–368, 372–373 SOCS1 interleukin-15, 368–370, 372–373 antitumor immunity, 319–320 CISH in differentiation, 317–318 differentiation, 314 development Tregs, 315 cell precursor ﬂux regulation, 282–286, 280 SOCS3 and helper T cells, 321 commitment in early development tumor necrosis factor in development and function, 104 phase 1, 278–279 TCF1, 274, 277, 282 phase 2, 280–281 TGF-b. See Transforming growth factor b phase 3, 281–282 early phases THRIL, 304 phase 1, 274 Thymic stromal lymphoprotein (TSLP), 329, 351, 353 phase 2, 274–275 TLRs. See Toll-like receptors phase 3, 275–276 TNF. See Tumor necrosis factor GATA3 role, 277–278 Toclizumab, therapy initiation by environmental signals and Castleman disease, 89 transcription factors, 276 giant cell arteritis, 92 interleukin-7 in phase 1/phase 2 transition, juvenile idiopathic arthritis, 90 279–280 myocardial infarction, 94 overview, 273–274 neuromyelitis optica, 92 g chain family cytokine function polymyalgia rheumatica, 92–93 CD8þ T-cell development and differentiation, 16 rheumatoid arthritis, 89–90 development, 10–11 systemic sclerosis, 90–91 T helper cell differentiation, 12–16 Toll-like receptors (TLRs), type I interferon regulation via Tregs, 11–12 interferon regulatory factor, 206–208

469

TRAF3, 347 Tumor necrosis factor receptor-associated periodic TRAIL, 417, 421–422 syndrome (TRAPS), 267 Transforming growth factor b (TGF-b) Tumor-associated macrophage (TAM) regulatory T-cell regulation, 350–351 anticancer therapeutic response, 421–423 Th cell fate determination, 329–330 biomarker utilization in cancer, 419–421 TRAPS. See Tumor necrosis factor receptor-associated overview, 413 periodic syndrome tumor growth and progression role, 415–416 TSLP. See Thymic stromal lymphoprotein Tumor-associated neutrophil (TAN) Tumor necrosis factor (TNF) anticancer therapeutic response, 421–423 functions biomarker utilization in cancer, 419–421 adaptive immunity, 104 tumor growth and progression role, 416–419 B-cell development and function, 105 bone homeostasis, 103–104 U brain, 105 cell death, 103 UC. See Ulcerative colitis ectodermal development, 104 Ulcerative colitis (UC) inflammation, 103 g chain family cytokine studies, 20 lymphoid organs, 104 interleukin-10, 159, 161 overview of family, 99–103 interleukin-22 therapy, 170–172 survival signaling, 103 Ustekinumab, 151 T-cell development and function, 104 wound healing, 103 long noncoding RNA regulation of tumor necrosis V factor a, 302 Vascular endothelial growth factor (VEGF), 418, 459 noncanonical coreceptors and ligands, 111–112 VAT. See Visceral adipose tissue prospects for study, 114 VEGF. See Vascular endothelial growth factor regulation, 111, 113–114 Visceral adipose tissue (VAT), interleukin-33 in signaling homeostasis, 243–244, 355 bidirectional signaling, 107 induced juxtaposition, 105–107 membrane anchoring of ligand and receptor, 107– X 108 Xist, 294 pathways, 111 X-linked severe combined immunodeficiency (XSCID), protein-binding motifs, 110–111 IL2RG mutations, 2 re-anchoring, 107, 109–110 XSCID. See X-linked severe combined immunodeficiency

470